SOLAI Ltd Faces Dual NYSE Delisting Threat Over Market Cap, Equity, and Share Price Non-Compliance
Summary
SOLAI Ltd received an additional NYSE non-compliance notice for market capitalization and stockholders' equity, adding to its existing share price non-compliance and significantly increasing delisting risk.
Key Events
-
Additional NYSE Non-Compliance Notice
SOLAI received a letter dated April 27, 2026, notifying it of non-compliance with NYSE's continued listing standards due to its average total market capitalization being less than US$50 million over a 30-trading-day period and stockholders' equity being less than US$50 million as of December 31, 2025.
-
Compounding Delisting Risk
This new notice adds to a previous non-compliance warning from January 29, 2026, regarding the minimum US$1.00 average share price. The company now faces multiple independent delisting threats, with separate cure periods.
-
Action Required and Potential Consequences
The company has 90 calendar days to submit a business plan to the NYSE demonstrating how it intends to regain compliance within 18 months. Failure to do so, or if the company's ADSs trade below US$0.10, could result in suspension and delisting from the NYSE.
Analysis
SOLAI Ltd has received a second formal notice from the NYSE, citing non-compliance with market capitalization and stockholders' equity requirements. This compounds an existing delisting threat related to its minimum share price, as previously disclosed on February 27, 2026. Failure to submit an acceptable business plan within 90 days, or if shares trade below $0.10, could lead to suspension and delisting, severely impacting the company's liquidity and investor confidence. This is a critical risk to the company's ability to remain publicly traded on a major exchange.
At the time of this filing, SLAI was trading at $0.80 on NYSE in the Crypto Assets sector, with a market capitalization of approximately $14.8M. The 52-week trading range was $0.63 to $8.07. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.